Management of adjuvant mitotane therapy following resection of adrenal cancer

Endocrine

Volumn 42, Issue 3, 2012, Pages 521-525

  Terzolo, M ^a   Ardito, A ^a   Zaggia, B ^a   Laino, F ^a   Germano, A ^a   De Francia, S ^a   Daffara, F ^a   Berruti, A ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Adjuvant treatment; Adrenal cancer; Mitotane; Recurrence free survival

Indexed keywords

GLUCOCORTICOID; KI 67 ANTIGEN; MITOTANE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADJUVANT THERAPY; ADRENAL CANCER; ADRENAL INSUFFICIENCY; ADRENALECTOMY; AMINOTRANSFERASE BLOOD LEVEL; ATTENTION DEFICIT DISORDER; BILIRUBIN BLOOD LEVEL; CANCER PROGNOSIS; CANCER STAGING; DISEASE FREE SURVIVAL; DOCTOR PATIENT RELATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; EVIDENCE BASED MEDICINE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL DISEASE; GYNECOMASTIA; HUMAN; LIVER DISEASE; LOW DRUG DOSE; MALE SEXUAL DYSFUNCTION; MEDICAL DECISION MAKING; MEMORY DISORDER; MITOSIS INDEX; NEUROLOGIC DISEASE; OVERALL SURVIVAL; PATIENT COMPLIANCE; PATIENT SELECTION; PERSONAL EXPERIENCE; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; REVIEW; SIDE EFFECT; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; ADRENAL TUMOR; CASE MANAGEMENT; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PROGNOSIS;

ADRENAL GLAND NEOPLASMS; ANTINEOPLASTIC AGENTS, HORMONAL; CASE MANAGEMENT; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; MITOTANE; PROGNOSIS;

EID: 84878232047     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-012-9719-7     Document Type: Review

References (37)

1. B.L. Wajchenberg, M.A. Albergaria Pereira, B.B. Medonca et al., Adrenocortical carcinoma: clinical and laboratory observations. Cancer 88, 711-736 (2000)
2. A.P. Dackiw, J.E. Lee, R.F. Gagel, D.B. Evans, Adrenal cortical carcinoma. World J. Surg. 25, 914-926 (2001)
3. B. Allolio, M. Fassnacht, Adrenocortical carcinoma: clinical update. J. Clin. Endocrinol. Metab. 60, 273-287 (2006)
4. R. Bellantone, A. Ferrante, M. Boscherini et al., Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the italian national registry for adrenal cortical carcinoma. Surgery 122, 1212-1218 (1997)
5. P. Icard, P. Goudet, C. Charpenay et al., Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the french association of endocrine surgeons study group. World J. Surg. 25, 891-897 (2001)
6. R.F. Pommier, M.F. Brennan, An eleven-year experience with adrenocortical carcinoma. Surgery 112, 963-970 (1992)
7. D.E. Schteingart, A. Motazedi, R.A. Noonan, N.W. Thompson, Treatment of adrenal carcinomas. Arch. Surg. 117, 1142-1146 (1982)
8. B. Bodie, A.C. Novick, J.E. Pontes et al., The cleveland clinic experience with adrenal cortical carcinoma. J. Urol. 141, 257-260 (1989)
9. A.A. Nelson, G. Woodard, Severe adrenal cortical atrophy (cytotoxic) and hepatic damage produced in dogs by feeding 2,2-bis(parachlorophenyl)-1,1- dichloroethane (DDD or TDE). Arch. Pathol. 48, 387-394 (1949)
10. I. Veytsman, L. Nieman, T. Fojo, Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J. Clin. Oncol. 27, 4619-4629 (2009)
11. S. Hahner, M. Fassnacht, Mitotane for adrenocortical carcinoma treatment. Curr. Opin. Investig. Drugs. 6, 386-394 (2005)
12. L. Cerquetti, C. Sampaoli, D. Amendola et al., Mitotane sensitizes adrenocortical cancer cells to ionizing radiations by involvement of the cicli B1/CDK complex in G2 arrest and mismatch repair enzymes modulation. Int. J. Oncol. 37, 493-501 (2010)
13. D.E. Schteingart, Adjuvant mitotane therapy of adrenal cancer-use and controversy. N. Engl. J. Med. 356, 2415-2418 (2007)
14. R. Vassilopoulou-Sellin, V.F. Guinee, M.J. Klein et al., Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 71, 3119-3123 (1993)
15. H.R. Haak, J. Hermans, C.J. van de Velde et al., Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br. J. Cancer 69, 947-951 (1994)
16. E. Baudin, G. Pellegriti, M. Bonnay et al., Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o, p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92, 1385-1392 (2001)
17. L. Barzon, F. Fallo, N. Sonino, O. Daniele, M. Boscaro, Adrenocortical carcinoma: experience in 45 patients. Oncology 54, 490-496 (1997)
18. D.E. Schteingart, G.M. Doherty, P.G. Gauger et al., Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr. Relat. Cancer 12, 667-680 (2005)
19. M. Terzolo, A. Angeli, M. Fassnacht et al., Adjuvant mitotane treatment for adrenocortical carcinoma. N. Engl. J. Med. 356, 2372-2380 (2007)
20. J. Bertherat, J. Coste, X. Bertagna, Adjuvant mitotane in adrenocortical carcinoma. Letter to the Editor. N. Engl. J. Med. 357, 1256-1257 (2007)
21. H. Huang, T. Fojo, Adjuvant mitotane for adrenocortical cancer-a recurring controversy. J. Clin. Endocrinol. Metab. 93, 3730-3732 (2008)
22. E.G. Grubbs, G.G. Callender, Y. Yan Xing et al., Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. Ann. Surg. Oncol. 17, 263-270 (2010)
23. M. Fassnacht, S. Johanssen, W. Fenske et al., Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J. Clin. Endocrinol. Metab. 95, 4925-4932 (2010)
24. B. Wängberg, A. Khorram-Manesh, S. Jansson et al., The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Endocr. Relat. Cancer 17, 265-272 (2010)
25. I.G. Hermsen, M. Fassnacht, M. Terzolo et al., Plasma concentrations of o, p'DDD, o, p'DDA, and o, p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J. Clin. Endocrinol. Metab. 96, 1844-1851 (2011)
26. A. Ardito, A. Al Ghuzlan, M. Fassnacht et al., Mitotane levels affect the outcome of patients treated adjuvantly following radical resection of adrenocortical cancer (ACC), in 93th Endocrine Society Meeting, Boston, 4-7 July 2011
27. A. Berruti, M. Fassnacht, E. Baudin et al., Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. J. Clin. Oncol. 28, e401-e402 (2010)
28. M. Fassnacht, R. Libé, M. Kroiss, B. Allolio, Adrenocortical carcinoma: a clinician's update. Nat. Rev. Endocrinol. 7, 323-335 (2011)
29. M. Volante, E. Bollito, P. Sperone et al., Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. Histopathology 55, 535-543 (2009)
30. S. Mauclère-Denost, S. Leboulleux, I. Borget et al., High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up. Eur. J. Endocrinol. 166, 261-268 (2012)
31. M. Terzolo, A. Pia, A. Berruti et al., Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. J. Clin. Endocrinol. Metab. 85, 2234-2238 (2000)
32. F. Daffara, S. De Francia, G. Reimondo, B. Zaggia, E. Aroasio, F. Porpiglia, M. Volante, A. Termine, F. Di Carlo, L. Dogliotti, A. Angeli, A. Berruti, M. Terzolo, Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr. Relat. Cancer 15, 1043-1053 (2008)
33. M. Terzolo, A. Berruti, Adjunctive treatment of adrenocortical carcinoma. Curr. Opin. Endocrinol. Metab. 15, 221-226 (2008)
34. R.V. Hague, W. May, D.R. Cullen, Hepatic microsomal enzyme induction and adrenal crisis due to o, p'DDD therapy for metastatic adrenocortical carcinoma. Clin. Endocrinol. 31, 51-57 (1989)
35. N. Nancy Nader, G. Raverot, A. Emptoz-Bonneton et al., Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans. J. Clin. Endocrinol. Metab. 91, 2165-2170 (2006)
36. Y.Z. Xu, Y. Zhu, Z.J. Shen, J.Y. Sheng, H.C. He, G. Ma, Y.C. Qi, J.P. Zhao, Y.X. Wu, W.B. Rui, Q. Wei, W.L. Zhou, X. Xie, G. Ning, Significance of heparanase-1 and vascular endothelial growth factor in adrenocortical carcinoma angiogenesis: potential for therapy. Endocrine 40, 445-451 (2011)
37. J. Ye, Y. Qi, W. Wang, F. Sun, Q. Wei, T. Su, W. Zhou, Y. Jiang, W. Yuan, J. Cai, B. Cui, G. Ning, Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adrenocortical adenomas. Endocrine 41, 479-486 (2012)